Unlocking the Potential of Genetic Medicines Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
Location: United States, Pennsylvania, Philadelphia
Employees: 11-50
Total raised: $65.5M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | BioMotiv | biomotiv.c... |
| 17.10.2025 | Avego | avego.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.11.2023 | Series B | $41.5M | - |
| 11.12.2022 | Series B | $24M | - |
Mentions in press and media 17
| Date | Title | Description |
| 20.12.2023 | Philly Money Moves: Biotech firm Vivodyne raised $38M for lab-grown organ development | Money Moves is a column where we chart the raises, mergers and other funding news of tech companies across the region on the third Wednesday of the month. Have a tip? Email us at philly@technical.ly. Update: Mention of PolicyMap's Series A ... |
| 28.11.2023 | Aro Biotherapeutics Raises $41.5M Series B Financing | Aro Biotherapeutics, a Philadelphia, PA-based clinical stage biotechnology company, raised $41.5M in Series B funding. The round was led by Cowen Healthcare Investments, with participation from existing investors from Aro’s Series A financi... |
| 05.01.2023 | Monday Moves: 3 Philly biotech companies are starting 2023 with fresh funding | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly. ArriVent Biopharma raises $110 million Newtown Square-based biopharmaceutical company ArriVent Bioph... |
| 16.09.2022 | Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease | Philadelphia, PA, September 15, 2022 — Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Dru... |
| 11.08.2022 | Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease | PHILADELPHIA, PA., AUGUST 10, 2022 – Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designat... |
| 11.05.2022 | Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease | Results of recent studies demonstrate that Aro’s muscle-targeted Centyrin-siRNA conjugate robustly reduces toxic accumulation of muscle glycogen in a murine model of Pompe disease Presentation and posters illustrate first proof-of-concept ... |
| 31.03.2022 | Aro Biotherapeutics to Highlight Therapeutic Potential of Centyrin Oligonucleotide Conjugates at Upcoming Industry Conferences | Company to Present New Data Demonstrating Centyrin Oligonucleotide Conjugates Achieve Potent and Tissue-Specific Gene Knockdown Philadelphia, PA, March 30, 2022 – Aro Biotherapeutics, a biotechnology company pioneering the development of... |
| 06.01.2021 | Daily funding roundup - January 5th, 2021 | Blue Wire raised $5M; Emboline landed $10M; PostHog secured $12M; Citizen pickes up $73M Care Package Direct: Care Package Direct was founded during the pandemic with the intent to make health and safety surveillance and supplies as simple ... |
| 05.01.2021 | Philly life science orgs see leadership changes, strong funding to kick off 2021 | Power Moves is a column where we chart the comings and goings of talent across the region. Got a new hire, new gig or promotion? Email us: philly@technical.ly. Philadelphia’s life sciences sector has already seen a strong start to 2021 with... |
| 05.01.2021 | Aro Biotherapeutics Raises $88M in Series A Financing | Aro Biotherapeutics, a Philadelphia, PA-based biotechnology company pioneering the development of tissue-targeted genetic medicines, closed an $88m Series A financing. The round was led by Northpond Ventures and Cowen Healthcare Investments... |
Show more